Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease.
We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (BR) group was included to enable determination of the noninferiority of PPX relative to BR as the standard treatment.
Mizuno
Yoshikuni
Y
Department of Neurology, Juntendo University School of Medicine, Bunkyo, Tokyo, Japan. y_Mizuno@med.juntendo.ac.jp
Yanagisawa
Nobuo
N
Kuno
Sadako
S
Yamamoto
Mitsutoshi
M
Hasegawa
Kazuko
K
Origasa
Hideki
H
Kowa
Hisayuki
H
D000203:Activities of Daily Living; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D052160:Benzothiazoles; D001971:Bromocriptine / Q000627:therapeutic use*; D003710:Demography; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D000077487:Pramipexole; D011446:Prospective Studies; D011788:Quality of Life; D013844:Thiazoles / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D052160:Benzothiazoles; D013844:Thiazoles; D001971:Bromocriptine; D000077487:Pramipexole